Global Biomarker of Disease Market Growth (Status and Outlook) 2024-2030

Global Biomarker of Disease Market Growth (Status and Outlook) 2024-2030

Omics, proteomics, meta-bolomics technologies are used in biomarkers discovery and disease diagnosis. Biomarkers are used in risk assessment, molecular diagnostic, disease diagnosis, DNA fingerprinting and other molecular applications. Biomarkers enable pharmaceutical companies to analyze and discover novel drugs as demand for cost effective and efficient treatment dose is increasing. Biomarkers are used in drug validation and testing, sample preparation and assay development to eliminate complexity in discovery and development of novel drugs. Biomarkers of disease are used in identification of disease condition and also help in validation of clinical trials for novel drug.

The global Biomarker of Disease market size is projected to grow from US$ 31640 million in 2024 to US$ 79080 million in 2030; it is expected to grow at a CAGR of 16.5% from 2024 to 2030.

LPI (LP Information)' newest research report, the “Biomarker of Disease Industry Forecast” looks at past sales and reviews total world Biomarker of Disease sales in 2022, providing a comprehensive analysis by region and market sector of projected Biomarker of Disease sales for 2023 through 2029. With Biomarker of Disease sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Biomarker of Disease industry.

This Insight Report provides a comprehensive analysis of the global Biomarker of Disease landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Biomarker of Disease portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Biomarker of Disease market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Biomarker of Disease and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Biomarker of Disease.

According to the Global Use of Medicines 2023 released by IQVIA Institute, the global drug expenditure in 2022 was about US$1.48 trillion (excluding COVID vaccine and treatment-related expenses), and it is predicted to grow at a rate of 3%-6% in the next few years. In terms of drug expenditure, this number in China was about 166 billion dollars in 2022. It is expected that the expenditure on medicines will increase in the next few years. From the perspective of demand, the trend of population aging, the increase of residents’ wealth and the improvement of health awareness will drive the demand for medicines.

Global Use of Medicines 2023 shows that the U.S. market spent about US$ 62.9 billion on medicines in 2022 on a net ex-factory basis. Overall growth slows as the Inflation Reduction Act (IRA) spends US$64 billion to reduce prescription drug prices, and the adoption of new treatments is expected to increase over the next few years. Besides, ex-factory discounts and rebates in drug distribution, the impact of patent expiration, and generic or biosimilar competition will also affect the U.S. pharmaceutical market.

This report presents a comprehensive overview, market shares, and growth opportunities of Biomarker of Disease market by product type, application, key players and key regions and countries.

Segmentation by Type:
Sample Preparation
Assay Development
Biomarker Validation and Testing
Others

Segmentation by Application:
Pharmaceutical Companies
Government & Private Research Institutes
Academic Institutes
Medical Device Manufacturing Companies
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Segmentation by Type:
Sample Preparation
Assay Development
Biomarker Validation and Testing
Others

Segmentation by Application:
Pharmaceutical Companies
Government & Private Research Institutes
Academic Institutes
Medical Device Manufacturing Companies
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Aushon Biosystem
Bio-Rad Laboratories
Thermo Fisher Scientific Inc
Siemens AG
Eisai Co. Ltd
Roche Diagnostics Limited
Abbott Laboratories, Inc
Epistem Ltd
Ge Healthcare
Agilent Technologies Inc

Please note: The report will take approximately 2 business days to prepare and deliver.